$1.07 Earnings Per Share Expected for Zoetis Inc. (NYSE:ZTS) This Quarter

Wall Street brokerages forecast that Zoetis Inc. (NYSE:ZTS) will post earnings per share (EPS) of $1.07 for the current quarter, according to Zacks. Five analysts have provided estimates for Zoetis’ earnings. The lowest EPS estimate is $1.02 and the highest is $1.15. Zoetis posted earnings of $0.89 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 20.2%. The firm is expected to issue its next quarterly earnings results on Thursday, August 5th.

On average, analysts expect that Zoetis will report full-year earnings of $4.49 per share for the current year, with EPS estimates ranging from $4.40 to $4.55. For the next financial year, analysts expect that the business will post earnings of $5.02 per share, with EPS estimates ranging from $4.84 to $5.18. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Zoetis.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.04 by $0.22. The firm had revenue of $1.87 billion during the quarter, compared to analyst estimates of $1.73 billion. Zoetis had a return on equity of 55.11% and a net margin of 25.30%. The business’s revenue was up 22.0% compared to the same quarter last year. During the same period last year, the firm posted $0.95 EPS.

ZTS has been the subject of several research reports. Raymond James increased their price target on Zoetis from $166.00 to $192.00 and gave the stock an “outperform” rating in a research note on Friday, May 7th. Barclays raised their target price on Zoetis from $200.00 to $208.00 and gave the stock an “overweight” rating in a research note on Friday, May 7th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised their target price on Zoetis from $175.00 to $184.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 12th. Argus raised their target price on Zoetis from $185.00 to $195.00 and gave the stock a “buy” rating in a research note on Friday, May 28th. Finally, Bank of America upgraded Zoetis from a “neutral” rating to a “buy” rating and set a $180.00 target price for the company in a research note on Monday, March 8th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $184.38.

Shares of ZTS stock traded down $0.74 on Thursday, hitting $185.38. 1,630,719 shares of the stock were exchanged, compared to its average volume of 1,939,019. The company has a quick ratio of 2.47, a current ratio of 3.29 and a debt-to-equity ratio of 1.61. The company has a market capitalization of $88.01 billion, a price-to-earnings ratio of 49.93, a PEG ratio of 3.15 and a beta of 0.65. Zoetis has a one year low of $131.28 and a one year high of $187.37. The firm has a 50 day moving average price of $174.94.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 1st. Investors of record on Wednesday, July 21st will be issued a dividend of $0.25 per share. The ex-dividend date is Tuesday, July 20th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.54%. Zoetis’s dividend payout ratio is 25.97%.

In related news, EVP Heidi C. Chen sold 11,637 shares of the firm’s stock in a transaction dated Wednesday, April 21st. The stock was sold at an average price of $170.14, for a total transaction of $1,979,919.18. Following the transaction, the executive vice president now directly owns 36,282 shares of the company’s stock, valued at approximately $6,173,019.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Roxanne Lagano sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, May 19th. The shares were sold at an average price of $169.05, for a total value of $1,014,300.00. Following the transaction, the executive vice president now directly owns 53,642 shares in the company, valued at $9,068,180.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 19,692 shares of company stock worth $3,319,012. 0.17% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Y Intercept Hong Kong Ltd purchased a new position in Zoetis in the 4th quarter worth approximately $370,000. Tompkins Financial Corp purchased a new position in Zoetis in the 4th quarter worth approximately $361,000. Angeles Investment Advisors LLC increased its stake in Zoetis by 7.0% in the 4th quarter. Angeles Investment Advisors LLC now owns 6,459 shares of the company’s stock worth $1,069,000 after purchasing an additional 423 shares during the period. Teamwork Financial Advisors LLC grew its position in shares of Zoetis by 25.5% in the 4th quarter. Teamwork Financial Advisors LLC now owns 2,059 shares of the company’s stock worth $341,000 after buying an additional 419 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in shares of Zoetis by 15.6% in the 4th quarter. Russell Investments Group Ltd. now owns 447,248 shares of the company’s stock worth $73,946,000 after buying an additional 60,449 shares during the last quarter. 90.21% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: Derivative

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.